BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million
Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia...
Barchart Research What to Expect from BMRN Earnings BMRN Generated May 1, 2026 Current Price $54.06 EPS Estimate $$0.81 Consensus Rating Moderate Buy Average Move 4.13% BioMarin's Enzyme Portfolio Momentum...
Acquisition Adds Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease to BioMarin's...